Imaging functional brain connectivity : pharmacological modulation, aging and Alzheimer's disease

Klaassens, B.L.

Cover Page

The handle http://hdl.handle.net/1887/65052 holds various files of this Leiden University dissertation.

Author: Klaassens, B.L.
Title: Imaging functional brain connectivity : pharmacological modulation, aging and Alzheimer's disease
Issue Date: 2018-09-06

Chapter 2

Single-dose serotonergic stimulation shows widespread effects on functional brain connectivity

Bernadet L. Klaassens[a,b,c], Helene C. van Gorsel[d], Najmeh Khalili-Mahani[e], Jeroen van der Grond[b], Bradley T. Wyman[f], Brandon Whitcher[f], Serge A.R.B. Rombouts[a,b,c], Joop M.A. van Gerven[d]

[a]Leiden University, Institute of Psychology, Leiden, the Netherlands, [b]Leiden University Medical Center, Department of Radiology, Leiden, the Netherlands, [c]Leiden University, Leiden Institute for Brain and Cognition, Leiden, the Netherlands, [d]Centre for Human Drug Research, Leiden, the Netherlands, [e]McGill University, Montreal Neurological Institute, Montreal, Quebec, Canada, [f]Pfizer Inc., Cambridge, MA, USA

ABSTRACT

The serotonergic system is widely distributed throughout the central nervous system. It is well known as a mood regulating system, although it also contributes to many other functions. With resting state functional magnetic resonance imaging (RS-fMRI) it is possible to investigate whole brain functional connectivity. We used this non-invasive neuroimaging technique to measure acute pharmacological effects of the selective serotonin reuptake inhibitor sertraline (75 mg) in 12 healthy volunteers. In this randomized, double blind, placebo-controlled, crossover study, RS-fMRI scans were repeatedly acquired during both visits (at baseline and 3, 5, 7 and 9 h after administering sertraline or placebo). Within-group comparisons of voxelwise functional connectivity with ten functional networks were examined ($p < 0.005$, corrected) using a mixed effects model with cerebrospinal fluid, white matter, motion parameters, heart rate and respiration as covariates. Sertraline induced widespread effects on functional connectivity with multiple networks; the default mode network, the executive control network, visual networks, the sensorimotor network and the auditory network. A common factor among these networks was the involvement of the precuneus and posterior cingulate cortex. Cognitive and subjective measures were taken as well, but yielded no significant treatment effects, emphasizing the sensitivity of RS-fMRI to pharmacological challenges. The results are consistent with the existence of an extensive serotonergic system relating to multiple brain functions with a possible key role for the precuneus and cingulate.

INTRODUCTION

The central serotonergic system plays an important modulatory role and affects diverse functions like cognition, mood, appetite, sleep and sensorimotor activity. Different classes of serotonin (5-hydroxytryptamine, 5-HT) receptors exist, and they are distributed throughout the whole brain, including the cortex, limbic areas, hypothalamus, basal ganglia, brain stem and cerebellum [48-50, 109, 110]. The selective serotonin reuptake inhibitor (SSRI) sertraline increases the concentration of synaptic serotonin and is commonly prescribed as a treatment for depression and anxiety disorders [52].

Functional brain imaging shows that SSRIs change brain activation and perfusion in limbic and prefrontal regions, which have been identified as important mediators in emotional processing. However, SSRIs also influence many other brain structures, including the precuneus, basal ganglia, brain stem, cerebellum, hypothalamus, temporal, parietal and occipital areas [111-117].

Understanding the mechanism of action of the extensive system of serotonergic neurons requires a method for studying large-scale network interactions instead of isolated brain regions [83]. The resting state functional magnetic resonance imaging (RS-fMRI) technique allows an integral non-invasive investigation of these network interactions, taking into account the brain's comprehensive neural circuit [7, 118].

The main focus of most RS-fMRI studies on SSRIs has been functional connectivity of the default mode network (DMN), which includes the posterior cingulate, precuneus and medial prefrontal, temporal and parietal regions. The DMN, one of the most consistent networks, is affected in multiple mental disorders, including depression [88]. SSRI administration shows a reduction in functional DMN connectivity, indicating normalization of patterns as seen in depression [82, 84-87]. Yet, SSRIs are expected to change functional connections in brain regions beyond the DMN too [83].

Here, we apply a technique of repeated measures RS-fMRI and an analysis of region-to-network connectivity to study whole brain treatment effects of an SSRI in healthy young volunteers. We have shown the sensitivity of this approach for various other pharmacological challenges [76, 78-81]. Given the widespread distribution of serotonergic receptors in the brain and the involvement of serotonin in many brain functions, we hypothesize that a single-dose of the SSRI sertraline will not only affect the DMN but various resting state brain networks, related to emotional, sensory, motor, cognitive and executive functioning.

MATERIALS AND METHODS

Subjects

Twelve healthy young volunteers (mean age 23.0 ± 2.8, range 19-28; gender ratio 1:1; BMI 19-24 kg/m^2) were recruited to participate in the study. All subjects underwent a thorough medical screening at the Centre for Human Drug Research (CHDR) to investigate whether they met the inclusion and exclusion criteria. They had a normal history of physical and mental health and were able to refrain from using nicotine and caffeine during study days. Other exclusion criteria included positive drug or alcohol screen on study days, regular excessive consumption of alcohol (>4 units/day), caffeine (>6 units/day) or cigarettes (>5 cigarettes/day), use of concomitant medication 2 weeks prior to study participation and involvement in an investigational drug trial 3 months prior to administration. The study was approved by the medical ethics committee of the Leiden University Medical Center (LUMC) and the scientific review board of the CHDR. Written informed consent was obtained from each subject prior to study participation.

Study design

This was a single center, double blind, placebo-controlled, crossover study with sertraline 75 mg. To cover the interval of maximum concentrations of sertraline (T_{max}: 5.5-9.5 h, $T_{\frac{1}{2}}$: 26 h), five RS-fMRI scans were acquired during study days, one at baseline and four after administering sertraline or placebo (at 3, 5, 7 and 9 h post dosing). Each scan was followed by performance of computerized cognitive tasks (taken twice at baseline) on the NeuroCart® test battery, developed by the CHDR for quantifying pharmacological effects on the central nervous system (CNS). By including multiple measurements during the T_{max} interval, this repeated measures profile increases the statistical power of the analysis. Currently, there are no formal power calculation methods that allow estimating the sample size for testing whole brain functional variations. Our sample size was selected based on previous studies [76, 78-80] that demonstrated sufficient power to detect significant effects in repeated measures designs with 12 subjects. Sertraline and placebo were administered orally as capsules, matched for size and weight. To reduce the most common side effect of sertraline (nausea and vomiting), drug treatment was combined with granisetron 2 mg tablets on both study days. Multiple blood samples were taken during the course of the day to define the pharmacokinetic (PK) profile of sertraline in serum, its active metabolite desmethylsertraline and concentrations of cortisol and prolactin. Washout period between the two study days was at least 10 days. An overview of the study design is provided in Figure 2.1.

Figure 2.1. Schematic presentation of a study day. At baseline, one RS-fMRI scan was acquired, followed by the NeuroCart® CNS test battery (performed twice at baseline). After drug administration, four more RS-fMRI scans were acquired at time points T = 3, 5, 7 and 9 h post dosing, each time followed by the NeuroCart® test battery. During the day, seven blood samples were taken to measure the concentrations of (desmethyl) sertraline, cortisol and prolactin.

2

Blood sampling

Pharmacokinetics

Blood samples were collected in 4 mL serum tubes at baseline and 1.5, 3, 5, 6, 7 and 9 h post dosing, centrifuged (2000 *g* for 10 min) and stored at -40°C until analysis with liquid chromatography-tandem mass spectrometry (LC-MS/MS). PK parameters for sertraline and its active metabolite desmethylsertraline were calculated using a non-compartmental analysis. Maximum serum concentrations (C_{max}) and time of C_{max} (T_{max}) were obtained directly from the serum concentration data. The area under the serum concentration vs. time curve was calculated from time zero to the time of the last quantifiable serum measured concentration, which is equal to the last blood sample of the study day (AUC_{0-last}). The calculated PK parameters were not used for further analysis but investigated to validate the choice of time points of measurements.

Neuroendocrine variables

Blood samples were also obtained to determine cortisol and prolactin concentrations. Serum samples were taken in a 3.5 mL gel tube at baseline and 1.5, 3, 5, 6, 7 and 9 h post dosing, centrifuged (2000 *g* for 10 min) and stored at -40°C until analysis. Serum concentrations were quantitatively determined with electrochemiluminescence immunoassay. Cortisol and prolactin concentrations were subsequently used for statistical analysis using a mixed effects model with treatment, time, visit and treatment by time as fixed effects, subject, subject by treatment and subject by time as random effects and the average of the period baseline (pre-dose) values as covariate (SAS for Windows V9.1.3; SAS Institute, Inc., Cary, NC, USA). In the Results section, significant treatment effects (at *p* < 0.05) will be discussed.

NeuroCart® test battery

Each RS-fMRI scan was followed by functional CNS measures outside the scanner using the computerized NeuroCart® test battery measuring alertness, mood and calmness (Visual Analogue Scales (VAS) Bond & Lader), nausea (VAS Nausea), vigilance and visual motor performance

(Adaptive Tracking task), reaction time (Simple Reaction Time task), attention, short-term memory, psychomotor speed, task switching and inhibition (Symbol Digit Substitution Test and Stroop task), working memory (N-back task) and memory imprinting and retrieval plus social processing (Face Encoding and Recognition task) [95-103]. The Face Encoding and Recognition task was only performed twice during each day (at baseline and 7 h post dosing) because of limited different test versions. Duration of each series of NeuroCart® brain function tests was approximately 20 min (except for the baseline series when each task was executed twice within approximately 40 min). To minimize learning effects, training for the NeuroCart® tasks occurred during the screening visit within 3 weeks prior to the first study day.

Analysis

All post-dose repeatedly measured CNS endpoints were analyzed using a mixed effects model with treatment, time, visit and treatment by time as fixed effects, subject, subject by treatment and subject by time as random effects and the average of the period baseline (pre-dose) values as covariate (SAS for Windows V9.1.3; SAS Institute, Inc., Cary, NC, USA). As data of the Simple Reaction Time task were not normally distributed, these data were log-transformed before analysis and back transformed after analysis. The data of the Face Encoding and Recognition task were analyzed using a mixed effects model with treatment as fixed effect and subject as random effect and the baseline value as covariate. In the Results section, significant treatment effects (at $p < 0.05$) will be discussed.

Imaging

Scanning was performed at the LUMC on a Philips 3.0 Tesla Achieva MRI scanner (Philips Medical System, Best, The Netherlands) using a 32-channel head coil. During the RS-fMRI scans, all subjects were asked to close their eyes while staying awake. They were also instructed not to move their head during the scan. Instructions were given prior to each scan on both days. T1-weighted anatomical images were acquired once per visit. To facilitate registration to the anatomical image, each RS-fMRI scan was followed by a high-resolution T2*-weighted echo-planar scan. Duration was approximately 8 min for the RS-fMRI scan, 5 min for the anatomical scan and 30 s for the high-resolution scan. Heart rate and respiration signals were recorded during each scan.

RS-fMRI data were obtained with T2*-weighted echo-planar imaging (EPI) with the following scan parameters: 220 whole brain volumes, repetition time (TR) = 2180 ms; echo time (TE) = 30 ms; flip angle = 85°; field-of-view (FOV) = 220 x 220 x 130 mm; in-plane voxel resolution = 3.44 x 3.44 mm, slice thickness = 3.44 mm, including 10% interslice gap. The next parameters were used to collect T1-weighted anatomical images: TR = 9.7 ms; TE = 4.6 ms; flip angle = 8°; FOV = 224 x 177 x 168 mm; in-plane voxel resolution = 1.17 x 1.17 mm; slice thickness = 1.2 mm. Parameters of

high-resolution T2*-weighted EPI scans were set to: TR = 2200 ms; TE = 30 ms; flip angle = 80°; FOV = 220 x 220 x 168 mm; in-plane voxel resolution = 1.96 x 1.96 mm; slice thickness = 2.0 mm.

Analysis

All analyses were performed using the Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL, Oxford, United Kingdom) version 5.0.4 [119-121]. Each individual functional EPI image was inspected, brain-extracted and corrected for geometrical displacements due to head movement with linear (affine) image registration [122, 123]. Images were temporally filtered (with a high pass filter of 150 s) and spatially smoothed (with a 6 mm full-width half-maximum Gaussian kernel). Thereafter, scans were co-registered with the brain extracted high resolution T2*-weighted EPI scans (with 6 degrees of freedom) and T1 weighted images (using the Boundary-Based-Registration method) [122, 124]. The T1-weighted scans were non-linearly registered to the MNI 152 standard space (the Montreal Neurological Institute, Montreal, QC, Canada) using FMRIB's Non-linear Image Registration Tool. Registration parameters were combined to transform fMRI scans into standard space.

After preprocessing, RS-fMRI networks were extracted from each individual RS-fMRI dataset (12 subjects x 2 days x 5 scans = 120 datasets) using a dual regression analysis [36, 125] based on 10 predefined standard network templates. Confound regressors of time series from white matter (measured from the center of the corpus callosum) and cerebrospinal fluid (measured from the center of lateral ventricles) as well as six motion parameters (the estimated translation along and rotation around the x, y and z axes) were included in this analysis to account for non-neuronal signal fluctuations [126]. The 10 standard templates (see Figure 2.2) have previously been identified using a data-driven approach [10] and comprise the following networks: three visual networks (consisting of medial, occipital pole, and lateral visual areas), DMN (medial parietal, bilateral inferior-lateral-parietal and ventromedial frontal cortex), cerebellar network, sensorimotor network (supplementary motor area, sensorimotor cortex, and secondary somatosensory cortex), auditory network (superior temporal gyrus, Heschl's gyrus, and posterior insular), executive control network (medial-frontal areas, including anterior cingulate and paracingulate) and two frontoparietal networks (frontoparietal areas left and right). With the dual regression method, spatial maps representing voxel-to-network connectivity were estimated for each dataset separately in two stages for use in within-group comparisons. First, the weighted network maps were used in a spatial regression into each dataset. This stage generated 12 time series per dataset that describe the average temporal course of signal fluctuations of the 10 networks plus 2 confound regressors (cerebrospinal fluid and white matter). The six motion parameters, as estimated during motion correction, were inserted into the output files of this first stage for further analysis. Next, these time series were entered in a temporal regression into the same dataset. This resulted in a spatial map per network per dataset with regression coefficients referring to the weight of each voxel being associated with the characteristic signal

Figure 2.2. Ten functional resting state networks as identified by Smith et al. [10] in 36 healthy adults. To investigate sertraline effects, subject-wise spatial maps of these 10 networks were estimated using dual regression and entered in a mixed effects model for within-group comparisons ($p < 0.005$, corrected).

change of a specific network. The higher the value of the coefficient, the stronger the connectivity of this voxel with a given network. These individual statistical maps were subsequently used for higher level analysis.

Within-group comparisons for the contrast sertraline relative to placebo of voxelwise functional connectivity with each of the 10 functional networks were examined with a mixed effects general

linear model as used in our previous studies [76, 78, 80]. Average heart rate (beats/m) and respiration frequency (Hz) per RS-fMRI scan were added to the model as confound regressors, indicated as the most robust method to account for physiological variations [127]. In this model, treatment and time are used as fixed within-subject factors and subject as a random factor. More specifically, the treatment effect of sertraline vs. placebo was tested, with the subjects' means, and variance across time (each time point post dosing vs. baseline) modeled as covariates of no interest. Nonparametric permutation testing was used to estimate (with 5000 repeated permutations) for each network whether connectivity was significantly different on sertraline relative to placebo days. The resulting voxelwise probability map was corrected for the familywise error using threshold-free cluster enhancement and by Bonferroni correction for the 10 separately investigated networks (by examining the results at $p < 0.005$) [128, 129].

RESULTS

Pharmacokinetics

The T_{max} of serum sertraline varied between 2.90 and 6.92 h (mean T_{max}: 3.93 ± 1.34) and between 2.90 and 6.92 h (mean T_{max}: 4.01 ± 1.44) for desmethylsertraline. C_{max} for sertraline was between 14.40 and 52.80 ng/mL (mean C_{max}: 31.06 ± 11.84) and for desmethylsertraline between 4.50 and 17.10 ng/mL (mean C_{max}: 10.08 ± 3.84). AUC_{0-last} was between 78.17 and 305.60 ng*h/mL (mean AUC_{0-last}: 173.90 ± 69.62) for sertraline and between 5.16 and 98.30 ng*h/mL (mean AUC_{0-last}: 50.75 ± 27.65) for desmethylsertraline (see Figure 2.3 for individual and median sertraline PK time profiles).


Figure 2.3. Median (bold line) and individual (thin lines) pharmacokinetic profiles for sertraline concentrations in nanograms per milliliter on semi-log scale. Observations below limit of quantification were dismissed.

Cortisol and prolactin

There was a significant treatment effect on concentrations of cortisol (with $F = (1, 10)$ 17.87, $p < 0.01$). As shown in Figure 2.4, cortisol concentrations were increased after sertraline, relative to placebo. There was no significant treatment effect for prolactin concentrations.


Figure 2.4. Least squares means percent change from baseline profiles of cortisol concentrations (with standard errors of the mean as error bars).

NeuroCart® test battery

There were no significant treatment effects on measures of cognitive performance. Non-significant trends were found for the VAS Calmness (with $F = (1, 8)$ 5.11, $p = 0.054$: sertraline < placebo), the VAS Mood (with $F = (1, 8)$ 4.12, $p = 0.076$: sertraline < placebo) and the VAS Nausea (with $F = (1, 10)$ 3.84, $p = 0.078$: sertraline > placebo).

Imaging

Functional connectivity changes caused by sertraline were observed in relation to seven functional networks (see Figure 2.5 for statistical maps of the results; $p < 0.005$, corrected). The colors in Figure 2.5 match the colors of Figure 2.2 with regard to the defined networks. In Figure 2.2, the network that was investigated is shown, whereas in Figure 2.5, we show the regions in the brain that have altered connectivity with this network. Specifications of effects (cluster size and peak *t*-value of the clusters) are provided in Table 2.1. Compared to placebo, connections with the following networks were altered after administering sertraline:

Default mode network
Functional connectivity of the anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), medial prefrontal cortex and precuneus (orange in Figure 2.5a) with the DMN (orange in Figure 2.2) was decreased after sertraline compared to placebo.

Executive control network
Functional connectivity of the limbic system (including the ACC, PCC, thalamus, amygdala and hippocampus), precuneus, midbrain and medial prefrontal cortex (blue in Figure 2.5b) with the executive control network (blue in Figure 2.2) was decreased after sertraline compared to placebo.

Visual networks
Functional connectivity of the occipital cortex, ACC, PCC, precuneus, medial prefrontal cortex and small parts of the cerebellum (red in Figure 2.5c) with the three visual networks (red in Figure 2.2) was decreased after sertraline compared to placebo.

Sensorimotor network
Functional connectivity of the ACC, PCC, precuneus, central gyri and supplementary motor cortex (green in Figure 2.5d) with the sensorimotor network (green in Figure 2.2) was decreased after sertraline compared to placebo.

Auditory network
Functional connectivity was increased between the precuneus and PCC (pink in Figure 2.5e) and the auditory network (pink in Figure 2.2) after sertraline compared to placebo.

Common regions
For each of these networks, treatment effects were found in two common areas: the precuneus and PCC. In Figure 2.6 these effects are shown for each network in their corresponding color with the precuneus and PCC depicted in pale brown. Regions of effect within the precuneus and PCC were chosen to visualize the time profiles of changes in connectivity in relation to the networks (Figure 2.6a-e).

Figure 2.5. Spatial maps (with coordinates in mm) of sertraline-induced (a) decreases in functional connectivity between the ACC, PCC, precuneus and medial prefrontal cortex (orange) and the default mode network; (b) decreases in functional connectivity between the limbic system, precuneus, medial prefrontal cortex and midbrain (blue) and the executive control network; (c) decreases in functional connectivity between the occipital cortex, PCC, ACC, precuneus, medial prefrontal cortex and cerebellum (red) and the visual networks; (d) decreases in functional connectivity between the ACC, PCC, precuneus, central gyri and supplementary motor cortex (green) and the sensorimotor network; (e) increases in functional connectivity between the PCC and precuneus (pink) and the auditory network ($p < 0.005$, corrected). Coronal and axial slices are displayed in radiological convention (left = right).

Table 2.1. Overview of significant decreases and increases in functional connectivity as estimated with threshold-free cluster enhancement (*p* < 0.005, corrected)

Network	Region (Harvard-Oxford)		t*	x	y	z	Cluster size
Default mode network	ACC, frontal pole (including frontal medial cortex, paracingulate gyrus)	B/M	5.28	16	42	-18	2703
	inferior and middle frontal gyrus	R	5.33	46	26	32	1060
	parahippocampal gyrus	R	4.74	-14	-10	-30	273
	ACC, paracingulate gyrus	L	4.56	-12	46	4	193
	PCC, precuneus cortex	R	5.31	24	-56	6	100
	posterior superior temporal gyrus	R	4.89	66	-26	6	96
	pre- and postcentral gyrus	R	3.96	36	-20	40	90
	angular gyrus, posterior supramarginal gyrus	R	4.57	38	-50	34	83
	frontal pole	L	4.86	-44	40	2	82
Executive control network	limbic system (including amygdala, hippocampus, thalamus), temporal pole, PCC, midbrain	B/M	6.24	52	12	-4	11381
	superior lateral occipital cortex, cuneal cortex, precuneus cortex	L/M	4.13	-18	-62	42	432
	ACC, frontal medial cortex	M	4.4	-2	24	-2	295
	PCC, precuneus cortex	R	4.77	16	-56	32	243
	frontal pole (including frontal medial cortex, paracingulate gyrus)	L	4.65	-8	56	6	140
Visual network 1	occipital cortex (including fusiform gyrus, lingual gyrus, intra- and supracalcarine cortex, cuneal cortex extending into precuneus cortex)	B/M	5.55	-18	-68	-4	6592
Visual network 2	occipital cortex (including fusiform gyrus, lingual gyrus, calcarine cortex, cuneal cortex)	B/M	5.46	-2	-86	-12	1463
Visual network 3	lateral occipital, frontal, temporal and parietal cortex, cerebellum, PCC, precuneus cortex, pre- and postcentral gyrus	B	5.78	20	-80	26	28546
	ACC, paracingulate gyrus, subcallosal cortex, frontal medial cortex	B	5.05	34	42	-2	3757
	ACC, PCC, precentral gyrus, (middle and superior) frontal gyrus	R	4.59	12	-10	38	331
	precentral gyrus, (middle and superior) frontal gyrus	L	4.96	-30	2	46	111
Sensorimotor network	ACC, PCC, precuneus cortex, supplementary motor area, pre- and postcentral gyrus	B/M	7.26	8	2	60	9262
	ACC, paracingulate gyrus	L	4.2	-8	26	26	112
Auditory network	PCC, precuneus cortex, pre- and postcentral gyrus	B	4.48	-6	-44	52	125

Abbreviations: L = left, R = right, B = bilateral, M = midline, ACC = anterior cingulate cortex, PCC = posterior cingulate cortex. Voxel dimension = 2 mm x 2 mm x 2 mm (voxel volume 0.008 mL). * = uncorrected peak *t*-value within cluster.

2

Figure 2.6. Alterations in functional connectivity after sertraline administration within the precuneus and PCC (shown in pale purple) for the different networks. Plots visualize the corresponding average time profiles of changes in functional connectivity for sertraline (dotted line) and placebo (continuous line) conditions for (a) the auditory network; (b) the sensorimotor network; (c) the default mode network; (d) the medial visual network; (e) the executive control network (z-values with standard errors of the mean as error bars). Coronal and axial slices are displayed in radiological convention (left = right).

DISCUSSION

Sertraline induced widespread alterations in functional connectivity with multiple resting state networks in the brain. In line with Schaefer et al. [83] these alterations were primarily decreases in connectivity. Effects in the DMN, executive control network and limbic-frontal circuitry are mostly in agreement with earlier RS-fMRI studies on SSRI effects [82, 84-87]. New findings were a lowering of connectivity within visual networks and alterations in functional connectivity of the sensorimotor and auditory network with the cingulate cortex and precuneus. The PK time profile was consistent with our repeated measures, taken at appropriate time points when the largest effects could be expected. Post hoc investigation of connectivity changes over time suggests that sertraline might sometimes suppress regular diurnal fluctuations, similar to the effect we found on cortisol. Consistent with other literature, cortisol concentrations were slightly higher after SSRI administration [104, 105], as opposed to a gradual decrease during placebo days. The paucity of effects on cognitive performance implies that RS-fMRI is highly sensitive and appropriate as a measure of a serotonergic challenge when compared to neuropsychological testing.

Default mode and executive control network

Connectivity within the DMN (precuneus, ACC, PCC and medial prefrontal cortex) was decreased after exposure to sertraline. Furthermore, administration of sertraline led to decreased connectivity between the executive control network and the limbic system (including cingulate cortex, amygdala, hippocampus and thalamus), medial prefrontal cortex and the midbrain. The midbrain's median and dorsal raphe nuclei are the major source of serotonin release to the cerebral cortex, especially to the forebrain [47, 109] and are therefore considered to play an important role in SSRI enhancement [130, 131]. The desirable effects of SSRIs on mood are hypothesized to be mainly due to improved functionality and regulation of 5-HT_{1A} (concentrated in the limbic system, especially the hippocampus, cortical areas as the cingulate and raphe nuclei) and $5\text{-HT}_{2A/C}$ (represented in the limbic system, cortex, basal ganglia and choroid plexus) receptors [47, 49, 52, 110, 132]. Inhibitory 5-HT_{1A} receptors have a higher affinity for 5-HT than excitatory 5-HT_2 receptors [133]. Consequently, the net result of elevation of serotonin is a reduction of serotonergic activity at low concentrations, followed by stimulation at higher levels. Furthermore, after acute SSRI administration, serotonin reuptake inhibition is attenuated by activation of 5-HT_{1A} autoreceptors in the raphe nuclei, causing inhibition of cell firing [134]. The relatively limited pharmacological effect of a single 75 mg dose of sertraline could explain the decrease in functional connectivity that we found in many parts of the brain. However, compared to our healthy subjects, it is likely that the sensitivity of 5-HT receptors differs in depressed patients and changes with prolonged antidepressant treatment [135]. The effects on both networks point to alterations in limbic and frontal brain areas. Together, these regions have been regarded as related to emotional

functioning and processing [136], with deficits in the fronto-limbic circuitry shown in depressed patients [137-139]. Administering SSRIs might correct dysfunction of the fronto-limbic pathways as seen in depression [140], thereby influencing emotional and motivational information processing and integration. Interestingly, we found changes in connectivity with the precuneus and PCC for all five networks, both part of the DMN and mentioned as playing a central role in self-consciousness and self-reference [141]. The majority of previous RS-fMRI studies point to increased connectivity in depression, particularly of cortical midline structures as the precuneus, ACC and PCC with prefrontal areas [88]. The deviant pattern of the overactivated DMN, supporting internal mentation and integration of experiences, might refer to rumination; heightened self-awareness and -preoccupation during rest [142-144]. The effects that we observed include the sub- and perigenual ACC which are particularly associated with rumination [142]. The posterior parts of the DMN have been proposed as specific regions where normalization of abnormal activity and functional connectivity takes place after SSRI treatment [84, 145, 146].

Visual, auditory and sensorimotor networks

In the cortex, the frontal lobe contains the highest density of 5-HT terminals, but the midbrain's raphe nuclei project to all other cortical areas as well. High cortical concentrations of serotonin have been found in the primary visual, auditory and somatosensory cortices of primates [147-150]. The relative predominance of high affinity 5-HT_{1A} vs. low affinity 5-HT_2 receptors has been demonstrated in the prefrontal cortex [132, 151] but also in the visual and motor cortex of rhesus monkeys [152]. Again, this might explain the observed decrease in functional connectivity of the visual and sensorimotor networks after administering sertraline. Evidence for functional involvement of serotonin in the human visual system comes from observations in users of ecstasy (or 3,4-methylenedioxy-N-methylamphetamine; MDMA). MDMA induces an acute release and reuptake inhibition of serotonin, followed by serotonin depletion in the visual cortex, which is associated with changes in visual orientation processing [153]. Moreover, the 5-HT neuronal activity pattern seems to correspond to and facilitate tonic motor output in animals [154]. We found decreased connectivity of the sensorimotor network with the central gyri (the sensorimotor region) and the supplementary motor area. Improvement of motor behavior after giving SSRIs has been shown with task-related fMRI studies, accompanied by enhancement of brain motor activity in the sensorimotor cortex and supplementary motor area [155, 156]. Connectivity of the sensorimotor network and visual networks with the precuneus and (para)cingulate cortex was decreased in our study. The cingulate motor areas operate in concert with the limbic system for spatial orientation and executing voluntary movement [157, 158]. The precuneus has been identified as a major association area guiding visuo-spatial imagery, execution and preparation of complex motor behavior and attentive tracking [159, 160]. Connectivity of the precuneus and cingulate cortex with the auditory network was altered as well, although this time it concerned an increase instead of a decrease in connectivity. This corresponds to reverse

findings in depression of Sundermann et al. [88], who observed hypoconnectivity in areas that belong to the auditory network (left temporal cortex, insula). SSRIs have been used for treatment of tinnitus, the perception of a phantom sound [161]. FMRI studies on resting state connectivity in tinnitus patients illustrate the interplay between tinnitus and the auditory network, the DMN and limbic areas [162-166]. For example, the connectivity pattern of the precuneus/PCC region was discovered as positively correlating with emotional distress as measured with the tinnitus handicap inventory [165].

NeuroCart® test battery

Compared to placebo, sertraline did not result in any significant treatment effects on neurocognitive tasks of the NeuroCart® battery. There was a trend towards increasing nausea, decreasing calmness and decreasing mood on the VAS. The small size of our sample might be an explanation for the absence of behavioral effects. However, we did detect significant and large-scale effects on resting state connectivity, indicating the suitability of this method as a marker of efficacy compared to cognitive measures. These results suggest that RS-fMRI could be a useful technique in early CNS drug development, which generally requires the use of sensitive methods in relatively small study groups. Performance tasks are known to show limited and inconsistent effects after single acute dosing of an SSRI in healthy subjects [167], although we did not include tests that are potentially more sensitive to SSRIs as EEG recordings, REM-sleep and flicker discrimination tests [167, 168]. In task-related fMRI paradigms it was shown that acute neural changes take place in the limbic system and prefrontal circuitry [169-172]. Despite the instant neural changes after administration of an SSRI, improvements in mood and cognition usually begin only after a few weeks [173, 174]. One explanation for this apparent discrepancy is the acute effect of SSRIs on emotional bias [175-178], which could increase positive information processing, thereby slowly contributing to resolution of the depression [179]. Since the Face Encoding and Recognition task involves eliciting emotions, it was expected that an SSRI would exert the strongest acute effect on this task. Contrary to previous literature, we did not find such an effect in this study.

Limitations

Sertraline can be considered as one of the most selective SSRIs. Nevertheless, it still modulates catecholaminergic neurotransmission to some extent and noradrenergic and dopaminergic influences on functional connectivity cannot be ruled out. Sertraline is especially known for a low relative selectivity for 5-HT over dopamine [180]. The most common side effect during sertraline study days was nausea, which was reported by 50% of the subjects and lasted between 1.5 and 5 h, although this was never severe enough to lead to vomiting. This coincides with a non-significant trend towards experienced nausea on the VAS. Granisetron was added to prevent

nausea and vomiting [181], which as a side effect of sertraline could have altered the network responses or reduced the tolerability of the procedures [182]. To balance the study, granisetron was also administrated on placebo days. However, granisetron, being a very selective 5-HT$_3$ receptor antagonist, might have affected some central serotonergic effects of sertraline that are specifically related to 5-HT$_3$ functions [109]. Cortisol influences functional connectivity between the amygdala and medial prefrontal cortex, which might have confounded the results as well [183]. It is possible that the effects that were found in these areas are partially secondary to the small but significant increase in cortisol concentrations. Moreover, SSRIs potentially affect constriction of blood vessels [184] and as a consequence induce blood oxygen level dependent signal changes. This study cannot resolve the question whether observed fMRI effects reflect true neural changes or altered neurovascular coupling [185-187]. Yet, SSRIs do not typically influence the hemodynamic response [188] and in our study we did not find significant effects of sertraline on heart rate and respiration frequency, which would be considered the main source of causing vascular artifacts.

Conclusions and future perspectives

Using 10 different networks in a well-powered repeated measures design allowed us to confirm both earlier established hypotheses and to discover new, uninvestigated effects of SSRIs on resting state connectivity. The results verify that serotonergic tracts cover a substantial part of the brain and suggest that serotonin is implicated in processing emotional information, conscious coordination of motor behavior and higher-level perception of the environment, possibly with a central role for the precuneus and cingulate. Many network effects of sertraline showed a striking overlap with opposing connectivity changes that are reported in depression [88]. Confirmation of these outcomes will strengthen the confidence in this technique as a highly sensitive and specific method of drug investigation, which in the future may also be used to characterize new drugs under development.

Acknowledgements

2